Primary myelofibrosis, essential thrombocythemia, and polycythemia vera are myeloproliferative neoplasms that are associated with mutation in the JAK2 gene and, less often, with mutations in MPL or CALR genes. [1] [2] [3] [4] [5] These myeloproliferative neoplasms have highly variable propensities to either present with or to develop progressive bone marrow fibrosis: this fibrosing process is intrinsic to primary myelofibrosis and affects a significant subset of polycythemia vera patients and a very small subset of essential thrombocythemia patients. [6] [7] [8] [9] [10] [11] [12] Bone marrow fibrosis is measured by reticulin and trichrome stains of the bone marrow trephine biopsy and is graded on a semiquantitative scale. 13 The classification proposed by the World Health Organization (WHO) and updated in 2008 employs the European Consensus System to grade bone marrow fibrosis, which has four possible grades (0, 1, 2, and 3); distinction between these levels is based on the number, density, and thickness of silver-stained reticulin fibers as assessed by the pathologist (Table 1) . 14, 15 Previous systems used to grade bone marrow fibrosis included the Manoharan and Bauermeister schemes. 13, 14 Reticulin grade is not included among the factors used in primary myelofibrosis risk stratification systems, such as the Dynamic International Prognostic Scoring System 16, 17 and shows variable correlation with clinical parameters of disease progression, such as splenomegaly. However, increased reticulin grade is an adverse prognostic factor in primary myelofibrosis, essential thrombocythemia, and polycythemia vera. [18] [19] [20] [21] The level of reticulin fibrosis is included among the criteria used to establish a diagnosis of post-polycythemic myelofibrosis and post-thrombocythemic myelofibrosis, which represent clinically progressed stages of polycythemia vera and essential thrombocythemia, respectively. 22 Moreover, bone marrow fibrosis is a dynamic process and has been shown to resolve over time following eradication of the neoplastic clone by allogeneic stem cell transplantation in primary myelofibrosis. [23] [24] [25] Regression of bone marrow fibrosis is also associated with successful treatment of other diseases associated with bone marrow fibrosis, such as autoimmune myelofibrosis and chronic myelogenous leukemia. [26] [27] [28] The JAK1/JAK2 inhibitor ruxolitinib is a novel agent that has been shown to ameliorate clinical symptoms and splenomegaly and prolong survival in patients with primary myelofibrosis, post-thrombocythemic myelofibrosis and post-polycythemic myelofibrosis. [29] [30] [31] [32] [33] [34] [35] Although prior therapies used to treat primary myelofibrosis (hydroxyurea and interferon) have shown little or no effect on bone marrow fibrosis grade, 36,37 treatment with ruxolitinib has been associated with reduction and even complete resolution of bone marrow fibrosis. 38, 39 The selective JAK2 inhibitor fedratinib has also shown efficacy in treating patients with primary myelofibrosis, post-thrombocythemic myelofibrosis, and post-polycythemic myelofibrosis and similarly shows evidence of reduced reticulin fibrosis in treated patients. 40 This accumulating evidence suggests that reticulin grade may represent an additional parameter to measure treatment response, in conjunction with existing clinical and biological parameters such as splenomegaly, symptoms, peripheral counts, and JAK2 allele burden. 30, 31, 34, 35, 41 Indeed, a reticulin fibrosis grade of r1 (as well as normal age-adjusted normocellularity for primary myelofibrosis and polycythemia vera) is included among required criteria for a complete response to therapy in primary myelofibrosis, essential thrombocythemia, and polycythemia vera patients according to the recently published European LeukemiaNet guidelines. 42, 43 However, there has been some controversy as to the reproducibility of reticulin grading and its applicability to routine diagnosis setting outside of a clinical trial setting. [44] [45] [46] [47] [48] In order to address this issue, we examined the concordance of reticulin grading in a large number of patients with primary myelofibrosis, post-thrombocythemic myelofibrosis, and post-polycythemic myelofibrosis, in the context of clinical fedratinib trials. Our goal was to determine the reproducibility of the WHO-adopted reticulin grading system in patients before and on treatment with a JAK2 inhibitor. We also assessed the reproducibility of cellularity estimation in the same samples.
Materials and methods

Patients
The study included 261 patients with myeloproliferative neoplasms on three fedratinib (SAR302503) trials: one Phase 1/2 trial (38 patients), one Phase 2 trial (26 patients), and one Phase 3 trial (197 patients). The diagnoses were primary myelofibrosis in 120 patients (46%), post-polycythemia myelofibrosis in 54 patients (21%), and post-thrombocythemic myelofibrosis in 19 patients (7%). In 68 patients (26%), the myeloproliferative neoplasm subtype before study entry was not available. Before enrollment on the studies, 70% of patients had been treated with hydroxyurea and 5% of patients had received other cytotoxic agents. A total of 728 bone marrow biopsies were evaluated, with 249 biopsies taken at baseline (pre-fedratinib) and 479 biopsies taken on therapy.
Bone Marrow Examination
Bone marrow biopsies were examined for hematopoietic cellularity and fibrosis grade based on the hematoxylin and eosin, silver impregnation reticulin, and trichrome stains. For the Phase 3 and Phase 2 studies, hematoxylin and eosin, reticulin (Gordon and Sweet method), and trichrome (Masson with Wiegert Hematoxylin and Biberich) stains were performed at the Covance Central Laboratory (Indianapolis, IN, USA) according to the manufacturer's protocols. For the Phase 1/2 study, hematoxylin and eosin, reticulin, and trichrome stains were performed locally at different US institutions where the biopsies had originated. Trichrome stains were available for 659 biopsies (90.5% of total biopsies evaluated). Hematopoietic cellularity included only cells of the myeloid, erythroid, megakaryocytic, and lymphoid lineages; stromal cells were explicitly excluded from the cellularity assessment. Hematopoietic cellularity was scored in 10% increments from 0 to 100%. Reticulin fibrosis was graded according to the 2008 updated WHO classification guidelines, from grades 0 to 3 ( Table 1) . As recommended, reticulin fibers were graded only in areas of hematopoiesis. On the basis of agreement between the three hematopathologists before slide review, biopsies showing heterogeneous morphology with variability in reticulin fibers were graded according to the predominant reticulin grade (450% of hematopoietic area). For example, if a 60% of the biopsy demonstrated grade 1 and 40% of the biopsy showed grade 2, the final assigned grade was grade 1.
The three hematopathologists (OP, JT, and RH) examined the same slide under a multi-headed microscope and independently scored hematopoietic cellularity and reticulin fibrosis grade. The pathologists were blinded to the patient information (with the exception of patient age and gender) and vassarstats.net). The study protocol was approved by the corresponding institutional research ethics committees and/or institutional review boards before enrollment of patients, and the study was conducted in accordance with the principles set forth by the Declaration of Helsinki.
Results
Concordance of Hematopoietic Cellularity
Hematopoietic cellularity could be assessed in 692/728 biopsies (95.1%). Cellularity could not be evaluated in 36 biopsies because of inadequate/ insufficient material for accurate assessment-that is, limited biopsy sample or severe crush artifact. The correlations of cellularity assessment among the three pathologists are shown in Table 2 . The average correlation coefficient r value was 0.917. Complete agreement in cellularity assessment between the three pathologists (same or ± 10% cellularity) was observed in 565/692 biopsies (81.7%), whereas in 127 biopsies cellularity discordance between at least two of the pathologists was 420%.
Concordance of Fibrosis Grading
Fibrosis could be graded in 665/728 biopsies (91.3%). Fibrosis could not be evaluated in 63 biopsies because of a failed reticulin stain, absence of hematopoietic areas, or inadequate tissue sample. Distribution of the final fibrosis grades assigned by the pathologists was as follows: grade 0: 21 biopsies (3.2%), grade 1: 90 biopsies (13.5%), grade 2: 234 biopsies (35.2%), and grade 3: 320 biopsies (48.1%). Trichrome staining (available in 90.5% of samples) aided the fibrosis grading in which small, often patchy areas corresponding to bundles of thick reticulin fibers were found in grade 2 fibrosis, whereas confluent and extensively stained depositions were characteristically observed in grade 3 fibrosis (Table 1 ). In 23 cases where reticulin stain was suboptimal, trichrome stain revealed extensive collagen deposition and helped to confirm grade 3 fibrosis. Conversely, trichrome stain results did not change the final fibrosis grade in any cases with adequate reticulin stain. Figure 1 shows representative hematoxylin and eosin and reticulin stains for different fibrosis grades in which all the three pathologists agreed. For fibrosis grading, all three agreed on 552 biopsies (83.0%), two of the three agreed on 111 biopsies (16.7%), and the grading required consensus discussion in two biopsies (0.3%). The concordance of fibrosis grading between the pathologists is shown in Table 3 . The unweighted kappa coefficient was equal to or greater than 0.8 that, based on the standards for strength of agreement of the kappa coefficient, qualifies as substantial (0.61-0.80) or almost perfect (0.81-1) agreement according to Landis and Koch. 49 Figure 2 shows frequencies of agreement on individual grades among each pair of pathologists. The highest rate of agreement was observed in grade 3 cases (93.1, 94.0, and 94.4% for all pathologist pairs). For grades 0, 1, and 2, the rate of agreement was 85.3-88.5%. Considering all pathologist pairs together, the rate of agreement for grade 3 was significantly higher than the agreement for grade 2 (Po0.0001), grade 1 (P ¼ 0.0001), and grade 0 (P ¼ 0.03), whereas there was no significant difference 
Concordance of Fibrosis Grading in Pre-and Post-Fedratinib Groups
To evaluate reproducibility of fibrosis grading in patients undergoing treatment with fedratinib, we Fibrosis/cellularity grading in bone marrow performed separate analyses for the biopsies taken at baseline (pre-fedratinib treatment; n ¼ 233) and during or after fedratinib therapy (n ¼ 168); the latter group excluded all patients within the treatment group on the Phase 3 study, some of whom received placebo. The agreement between each pair of pathologists for the treated group in comparison to the baseline group is shown in Table 4 . Considering all pathologist pairs together, the rate of agreement for baseline samples was significantly higher than that for post-treatment samples (P ¼ 0.023). However, all kappa values for the treated group were at least in the 'substantial correlation' category (Table 4) .
Discussion
Bone marrow fibrosis of significantly varying degree may be associated with the three major myeloproliferative neoplasm entities either at presentation, such as in primary myelofibrosis, or upon disease progression in polycythemia vera and essential thrombocythemia. The updated 2008 WHO classification has adopted the European Consensus on grading of bone marrow fibrosis, 14 a four-tiered system with grades 0-3. 15 Development of bone marrow fibrosis represents a stepwise evolution from absent or minimal reticulin fibrosis to marked reticulin and/or collagen fibrosis often associated with osteosclerosis, 7-9 and precise fibrosis grade assignment is essential both for initially classifying myeloproliferative neoplasms and identifying disease progression. 15, 22, 28 Although currently reticulin fibrosis grade is not widely accepted for risk assessment in patients with primary myelofibrosis, recent studies have shown that higher grades of bone marrow fibrosis independently predict poor outcome. Thus, concomitant use of clinical and morphological scoring systems may allow a better prediction of survival and patient risk stratification. 18, 21, 28 Further study is needed to correlate changes in bone marrow fibrosis with clinical and biological markers of disease evolution in myeloproliferative neoplasms. In this study we investigated the reproducibility of the WHO fibrosis grading system in 261 patients with primary myelofibrosis, post-polycythemic myelofibrosis, and post-thrombocythemic myelofibrosis who were enrolled in trials with fedratinib, a selective JAK2 inhibitor by unweighted kappa statistics, a well-established approach for the evaluation of observer agreement for categorical data. 49 To the best of our knowledge, this is the largest study evaluating interobserver fibrosis grading agreement to date and it shows high concordance of fibrosis grading for the entire cohort, with a kappa coefficient equal to or greater than 0.8 for all pathologist pairs (Table 3 and Figure 1 ). All the three pathologists agreed on a particular grade in 83% samples, which is a higher rate than reported in the published literature. For example, Wilkins et al. 45 reported a fibrosis grading statistical analysis on 370 biopsies from patients with essential thrombocythemia using a log-linear modeling of pairwise interobserver agreement method, showing a strength of association for reticulin fibrosis of 5.1 (95% CI, 4.0-6.4) with the three hematopathologists agreeing within one grade of one another in 69% of cases. However, this study employed a 5-grade system (0-4) that would be expected to produce more frequent variance in grade between observers than a 4-grade system used in our study. Moreover, this study found a stronger agreement between pathologists scoring in the reticulin grade compared with all other criteria reported in the same study (such as megakaryocytic morphology and clustering) and even assignment of WHO diagnosis. This study therefore concluded that reticulin grade was the dominant independent predictor of the WHO diagnosis of essential thrombocythemia. 45 Interestingly, a Danish group has reported similar experience, in which the degree of concordance of morphological assessment among seven hematopathologists improved from 53% (CI, 46.6-58.5%) to 60% (CI, 54.1-65.8%) by adding reticulin fibrosis grade to the assessment criteria. 50 However, concerning the latter study the number of panelists was higher than that in our study (seven versus three), which would result in lower chance of complete agreement; in addition, the inclusion of many control specimens may have lowered the overall rate of concordance. The relatively high interobserver agreement rate of fibrosis grade in the current study could be explained by several factors. First, except for the Phase 1/2 study, hematoxylin and eosin, reticulin, and trichrome stains were performed centrally at the Covance Central Laboratory under optimized conditions that improved stain quality, especially consistency of reticulin fiber intensity. In biopsies with suboptimal reticulin stain, the staining was repeated and was only considered uninterpretable if the staining failed a second time. Second, a large proportion of the biopsies in the study demonstrated WHO grade 3 fibrosis (320 biopsies, 48.1%), which showed the highest rate of agreement between the three pathologists (93.1-94.4%). These results are not surprising, as it is generally easier to diagnose an end-stage pathologic process. The rates of agreement for grades 0, 1, and 2 were o90% and the rate of agreement was significantly lower when compared with grade 3. Finally, the WHO classification grading criteria were extensively discussed before reviewing the slides in a training session between the three pathologists. On the basis of this training session, the pathologists agreed to grade fibrosis only in areas of hematopoiesis following the strict adherence to the WHO fibrosis grading system. 15 Although the WHO Classification does not provide guidance on handling cases with mixed grades, the pathologists decided in advance to assign grade based on the grade comprising the majority of the hematopoietic area. It is not unusual to encounter biopsies with mixed grades, especially in biopsies from patients on therapy. 36, 37 We compared the concordance of fibrosis grading in baseline and samples to those taken from patients on therapy; such an analysis has never been reported before our knowledge. We found that there was significantly lower agreement in samples taken from patients on fedratinib therapy (P ¼ 0.023). Nevertheless, even in these treated samples, the kappa statistics for all observer pairs were still within the 'substantial correlation' or 'near perfect correlation' ranges. These results validate our approach and suggest high reproducibility of the WHO fibrosis grading system, 15 even in patients undergoing therapy with disease-modifying agents such as fedratinib.
During the slide review and grading, the pathologists were blinded to the patients' treatment status. However, retrospective review of the selected slides from the treated group showed frequent low-grade reticulin fibrosis in spite of significant collagen staining with trichrome, indicating a divergence between reticulin fibrosis and collagen fibers; these cases often showed persistent osteosclerosis as well (data not shown). This observation suggests that JAK2 inhibitors may alter the disease biology by causing regression of reticulin fibers before regression of collagen fibrosis or osteosclerosis. This notion is indirectly supported by a case report that showed complete resolution of bone marrow fibrosis only after 168 weeks of therapy with ruxolitinib, a JAK1/JAK2 inhibitor, 38 and particularly after long term (5 years) of ruxolitinib treatment 51 and is similar to findings reported after stem marrow transplantation in primary myelofibrosis. 24 A unified approach is needed to address the issues of fibrosis grade heterogeneity, which may have contributed to the lower fibrosis grading concordance in treated patients, as well as the divergence in some treated cases between lower reticulin grades in the presence of collagen on trichrome stain and significant osteosclerosis. The WHO grading system does not currently provide guidance on these issues but could be slightly modified to take into account these observations in treated patients. For example, the use of the 'majority' grade in heterogeneous cases could be adopted.
In an attempt to standardize fibrosis grading assessment, Teman et al 47 have proposed quantification of fibrosis and osteosclerosis by a computerassisted approach using a color deconvolution algorithm that graded reticulin staining as a percentage of black pixels in three representative areas in a core biopsy that were later averaged. Osteosclerosis was assessed by manually selecting the bony trabeculae on a scanned slide and calculating the ratio of bony trabecular area to total biopsy area. Although the idea of a consistent objective fibrosis scoring system is appealing, this computerassisted approach has practical limitations that preclude its clinical use currently. Moreover, evaluation of only three randomly selected hematopoietic areas (total area of 1.5 mm 2 ) may Fibrosis/cellularity grading in bone marrow generate a significant bias concerning objectivity, particularly in cases with heterogeneity of reticulin grade that require careful examination of the entire slide. 36, 37 In addition, Teman et al. 47 validated only the computer-assisted scoring of grades 2 and 3. If such computer-based system is to be employed in clinical practice, it is imperative that the scoring software also recognizes grades 0 and 1 for treatment efficacy assessment. We believe that visual assessment of fibrosis by a hematopathologist remains the current gold standard for the diagnosis and serial monitoring of patients with myeloproliferative neoplasms.
In conclusion, accurate grading of bone marrow fibrosis is important for the initial diagnosis, classification, and risk stratification of the different myeloproliferative neoplasm entities; in the new era of the JAK1/JAK2 and JAK2 inhibitor agents, reticulin grade is a compelling candidate, along with existing clinical and biological factors, to measure treatment response. 38 Our study showed that the current WHO fibrosis grading system 15 is practically applicable and highly reproducible for establishing baseline fibrosis and subsequent fibrosis grades (which may increase or decrease) in patients undergoing therapy.
